Yes. But if measuring before, during, and after is only one part of the needed validation, and you need to show an objective response to the cancer. As per above response.
Then Sheba 2 wont provide the validation we need being combo treatment.
It will provide insight & beneficial data, just not clinical validation of FTO.
If only Sheba 1 came after COH findings.
General Comments / Chat, page-8640
-
- There are more pages in this discussion • 2,628 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |